Takeda Oncology
Abha Dhaneshwar currently serves as a Research Senior Scientist at Takeda Oncology, focusing on in vivo pharmacology for early discovery and clinical stage cell engager therapeutics since June 2023. Previously, Abha held several positions at Jounce Therapeutics, Inc., progressing from Associate Scientist to Scientist, with responsibilities such as leading early discovery immuno-oncology programs and managing in vivo functions. Prior experience includes a Lead Research Associate role at the Belfer Center for Applied Cancer Science, where Abha developed non-small cell lung cancer models, and several research positions at prestigious institutions like Beth Israel Deaconess Medical Center and the University of Pennsylvania. Abha holds a Master's degree in Biotechnology from the University of Pennsylvania and a Bachelor's degree in Pharmaceutical Sciences from Bharati Vidyapeeth.
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.